{"id":2675,"date":"2018-06-22T12:22:18","date_gmt":"2018-06-22T06:52:18","guid":{"rendered":"https:\/\/www.delveinsight.com\/blog\/?p=2675"},"modified":"2024-05-14T14:27:20","modified_gmt":"2024-05-14T08:57:20","slug":"fatty-acid-amide-hydrolase-faah","status":"publish","type":"post","link":"https:\/\/www.delveinsight.com\/blog\/fatty-acid-amide-hydrolase-faah","title":{"rendered":"Fatty Acid Amide Hydrolase (FAAH) Inhibitor \u2013 an enzyme with novel therapeutic potential"},"content":{"rendered":"<p style=\"text-align: justify;\"><a href=\"https:\/\/www.delveinsight.com\/report-store\/fatty-acid-amide-hydrolase-faah-inhibitor-pipeline-insight\"><strong>Fatty acid amide hydrolase<\/strong><\/a> (FAAH) belongs to the serine hydrolase family of enzymes. The identification of this enzyme was led by the discovery and characterization of fatty acid amides, including anandamide and oleamide, as a fundamental class of endogenous signaling molecules. FAAH serves as the major metabolic regulator of many of the endogenous fatty acid amides, exhibiting a distribution consistent with its role in regulating their effects at their released sites of action.<\/p>\n<p style=\"text-align: justify;\">A number of research studies have demonstrated that genetic and pharmacological inactivation of FAAH produces <strong>analgesic, anti-inflammatory, anxiolytic, neurogenic, neuropsychiatric<\/strong>, and <strong>anti-depressant phenotypes<\/strong> without showing the undesirable side effects of direct <strong>cannabinoid receptor agonists<\/strong>, indicating that FAAH may be a promising therapeutic target.<\/p>\n<p style=\"text-align: justify;\">On the contrary, the pipeline of FAAH inhibitors is not very robust with only 5+ active products and no late-stage (Phase III) product. <strong>Janssen<\/strong> and <strong>Spring Works Therapeutics<\/strong> are among the key players developing drugs in the <strong>Phase II stage<\/strong>. However, in 2016,<strong> J&amp;J<\/strong> voluntarily suspended the development of <strong>JNJ-42165279<\/strong> in the wake of a French clinical trial that caused death of one volunteer. Later, the company initiated the <strong>Phase II trial<\/strong> in the United States, Romania, Europe, Australia, Canada, and Russia for Anxiety disorders. On the other hand, <strong>PF-04457845<\/strong> is being evaluated for a number of indications such as <strong>Osteoarthritis, <a href=\"https:\/\/www.delveinsight.com\/report-store\/post-traumatic-stress-disorder-ptsd-epidemiology-forecast\">Post-Traumatic Stress Disorder<\/a>, Cannabis use disorder, acute\/chronic pain, <a href=\"https:\/\/www.delveinsight.com\/report-store\/tourette-syndrome-epidemiology-forecast\">Tourette syndrome<\/a><\/strong>, and <strong>fear<\/strong>.<\/p>\n<p style=\"text-align: justify;\">In addition to this, quite a few top-ranking drug development companies such as <strong>Sanofi<\/strong> and <strong>Vernalis<\/strong> abandoned their FAAH programs for strategic reasons and inefficacy respectively.<\/p>\n<p style=\"text-align: justify;\">Although, therapeutic development of FAAH inhibitors is not the current market focus, the future scope of the enzyme inhibitors suggests that it can be utilized for various indications involving central nervous system due to its wide range of mechanism of action.<\/p>\n<p style=\"text-align: justify;\"><em>Ayushi Sinha<\/em><\/p>\n<p style=\"text-align: justify;\"><em>Associate Analyst <\/em><\/p>\n","protected":false},"excerpt":{"rendered":"<p>Fatty acid amide hydrolase (FAAH) belongs to the serine hydrolase family of enzymes. The identification of this enzyme was led by the discovery and characterization of fatty acid amides, including anandamide and oleamide, as a fundamental class of endogenous signaling molecules. FAAH serves as the major metabolic regulator of many of the endogenous fatty acid [&hellip;]<\/p>\n","protected":false},"author":1,"featured_media":2705,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"_editorskit_title_hidden":false,"_editorskit_reading_time":0,"_editorskit_is_block_options_detached":false,"_editorskit_block_options_position":"{}","advgb_blocks_editor_width":"","advgb_blocks_columns_visual_guide":"","footnotes":""},"categories":[17],"tags":[1664,1652,1653,1654,1663,1155,204,245,1657,1659,1655,1656,1661,1660,1370,706,533,1658,1665,1666],"industry":[17225],"therapeutic_areas":[17227,17245],"class_list":["post-2675","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-articles","tag-acutechronic-pain","tag-analgesic","tag-anti-inflammatory","tag-anxiolytic","tag-cannabis-use-disorder","tag-consultancy","tag-delveinsight","tag-fatty-acid-amide-hydrolase","tag-janssen","tag-jnj-42165279","tag-neurogenic","tag-neuropsychiatric","tag-osteoarthritis","tag-pf-04457845","tag-pharmaceutical-consulting","tag-pharmaceutical-industry","tag-sanofi","tag-spring-works-therapeutics","tag-tourette-syndrome","tag-vernalis","industry-pharmaceutical","therapeutic_areas-immunological-and-autoimmune-disorders","therapeutic_areas-neurology"],"acf":[],"yoast_head":"<!-- This site is optimized with the Yoast SEO Premium plugin v25.8 (Yoast SEO v25.8) - https:\/\/yoast.com\/wordpress\/plugins\/seo\/ -->\n<title>FAAH (Fatty Acid Amide Hydrolase Inhibitor)- Delveinsight<\/title>\n<meta name=\"description\" content=\"As per Delveinsight, the pipeline of FAAH inhibitors is not very robust with only 5+ active products and no late-stage (Phase III) product.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.delveinsight.com\/blog\/fatty-acid-amide-hydrolase-faah\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"FAAH (Fatty Acid Amide Hydrolase Inhibitor)- Delveinsight\" \/>\n<meta property=\"og:description\" content=\"As per Delveinsight, the pipeline of FAAH inhibitors is not very robust with only 5+ active products and no late-stage (Phase III) product.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.delveinsight.com\/blog\/fatty-acid-amide-hydrolase-faah\" \/>\n<meta property=\"og:site_name\" content=\"DelveInsight Business Research\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/DelveInsight-1423323754607782\/\" \/>\n<meta property=\"article:published_time\" content=\"2018-06-22T06:52:18+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2024-05-14T08:57:20+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2018\/06\/09021250\/p1b60p6flc1ugirdpk251nmasrl3.jpg\" \/>\n\t<meta property=\"og:image:width\" content=\"590\" \/>\n\t<meta property=\"og:image:height\" content=\"290\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"author\" content=\"DelveInsight\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:creator\" content=\"@DelveInsight\" \/>\n<meta name=\"twitter:site\" content=\"@DelveInsight\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"DelveInsight\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"FAAH (Fatty Acid Amide Hydrolase Inhibitor)- Delveinsight","description":"As per Delveinsight, the pipeline of FAAH inhibitors is not very robust with only 5+ active products and no late-stage (Phase III) product.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.delveinsight.com\/blog\/fatty-acid-amide-hydrolase-faah","og_locale":"en_US","og_type":"article","og_title":"FAAH (Fatty Acid Amide Hydrolase Inhibitor)- Delveinsight","og_description":"As per Delveinsight, the pipeline of FAAH inhibitors is not very robust with only 5+ active products and no late-stage (Phase III) product.","og_url":"https:\/\/www.delveinsight.com\/blog\/fatty-acid-amide-hydrolase-faah","og_site_name":"DelveInsight Business Research","article_publisher":"https:\/\/www.facebook.com\/DelveInsight-1423323754607782\/","article_published_time":"2018-06-22T06:52:18+00:00","article_modified_time":"2024-05-14T08:57:20+00:00","og_image":[{"width":590,"height":290,"url":"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2018\/06\/09021250\/p1b60p6flc1ugirdpk251nmasrl3.jpg","type":"image\/jpeg"}],"author":"DelveInsight","twitter_card":"summary_large_image","twitter_creator":"@DelveInsight","twitter_site":"@DelveInsight","twitter_misc":{"Written by":"DelveInsight","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"WebPage","@id":"https:\/\/www.delveinsight.com\/blog\/fatty-acid-amide-hydrolase-faah","url":"https:\/\/www.delveinsight.com\/blog\/fatty-acid-amide-hydrolase-faah","name":"FAAH (Fatty Acid Amide Hydrolase Inhibitor)- Delveinsight","isPartOf":{"@id":"https:\/\/www.delveinsight.com\/blog\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.delveinsight.com\/blog\/fatty-acid-amide-hydrolase-faah#primaryimage"},"image":{"@id":"https:\/\/www.delveinsight.com\/blog\/fatty-acid-amide-hydrolase-faah#primaryimage"},"thumbnailUrl":"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2018\/06\/09021250\/p1b60p6flc1ugirdpk251nmasrl3.jpg","datePublished":"2018-06-22T06:52:18+00:00","dateModified":"2024-05-14T08:57:20+00:00","author":{"@id":"https:\/\/www.delveinsight.com\/blog\/#\/schema\/person\/5fbf6ca478835d03fdb5e17d905b520a"},"description":"As per Delveinsight, the pipeline of FAAH inhibitors is not very robust with only 5+ active products and no late-stage (Phase III) product.","inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.delveinsight.com\/blog\/fatty-acid-amide-hydrolase-faah"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.delveinsight.com\/blog\/fatty-acid-amide-hydrolase-faah#primaryimage","url":"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2018\/06\/09021250\/p1b60p6flc1ugirdpk251nmasrl3.jpg","contentUrl":"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2018\/06\/09021250\/p1b60p6flc1ugirdpk251nmasrl3.jpg","width":590,"height":290,"caption":"enzymes FAAH"},{"@type":"WebSite","@id":"https:\/\/www.delveinsight.com\/blog\/#website","url":"https:\/\/www.delveinsight.com\/blog\/","name":"DelveInsight Business Research","description":"Blog","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.delveinsight.com\/blog\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.delveinsight.com\/blog\/#\/schema\/person\/5fbf6ca478835d03fdb5e17d905b520a","name":"DelveInsight","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.delveinsight.com\/blog\/#\/schema\/person\/image\/","url":"https:\/\/secure.gravatar.com\/avatar\/afdd550c64e18f6ad8957080b017c6ae55f4916951d641d3cd40264176aa0e86?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/afdd550c64e18f6ad8957080b017c6ae55f4916951d641d3cd40264176aa0e86?s=96&d=mm&r=g","caption":"DelveInsight"}}]}},"author_meta":{"display_name":"DelveInsight","author_link":"https:\/\/www.delveinsight.com\/blog\/author\/gtadmin"},"featured_img":"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2018\/06\/09021250\/p1b60p6flc1ugirdpk251nmasrl3-300x147.jpg","coauthors":[],"tax_additional":{"categories":{"linked":["<a href=\"https:\/\/www.delveinsight.com\/blog\/articles\/\" class=\"advgb-post-tax-term\">Articles<\/a>"],"unlinked":["<span class=\"advgb-post-tax-term\">Articles<\/span>"]},"tags":{"linked":["<a href=\"https:\/\/www.delveinsight.com\/blog\/articles\/\" class=\"advgb-post-tax-term\">acute\/chronic pain<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/articles\/\" class=\"advgb-post-tax-term\">analgesic<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/articles\/\" class=\"advgb-post-tax-term\">anti-inflammatory<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/articles\/\" class=\"advgb-post-tax-term\">anxiolytic<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/articles\/\" class=\"advgb-post-tax-term\">Cannabis use disorder<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/articles\/\" class=\"advgb-post-tax-term\">consultancy<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/articles\/\" class=\"advgb-post-tax-term\">DelveInsight<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/articles\/\" class=\"advgb-post-tax-term\">Fatty acid amide hydrolase<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/articles\/\" class=\"advgb-post-tax-term\">Janssen<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/articles\/\" class=\"advgb-post-tax-term\">JNJ-42165279<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/articles\/\" class=\"advgb-post-tax-term\">neurogenic<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/articles\/\" class=\"advgb-post-tax-term\">neuropsychiatric<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/articles\/\" class=\"advgb-post-tax-term\">Osteoarthritis<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/articles\/\" class=\"advgb-post-tax-term\">PF-04457845<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/articles\/\" class=\"advgb-post-tax-term\">pharmaceutical consulting<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/articles\/\" class=\"advgb-post-tax-term\">Pharmaceutical Industry<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/articles\/\" class=\"advgb-post-tax-term\">Sanofi<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/articles\/\" class=\"advgb-post-tax-term\">Spring Works Therapeutics<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/articles\/\" class=\"advgb-post-tax-term\">Tourette syndrome<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/articles\/\" class=\"advgb-post-tax-term\">Vernalis<\/a>"],"unlinked":["<span class=\"advgb-post-tax-term\">acute\/chronic pain<\/span>","<span class=\"advgb-post-tax-term\">analgesic<\/span>","<span class=\"advgb-post-tax-term\">anti-inflammatory<\/span>","<span class=\"advgb-post-tax-term\">anxiolytic<\/span>","<span class=\"advgb-post-tax-term\">Cannabis use disorder<\/span>","<span class=\"advgb-post-tax-term\">consultancy<\/span>","<span class=\"advgb-post-tax-term\">DelveInsight<\/span>","<span class=\"advgb-post-tax-term\">Fatty acid amide hydrolase<\/span>","<span class=\"advgb-post-tax-term\">Janssen<\/span>","<span class=\"advgb-post-tax-term\">JNJ-42165279<\/span>","<span class=\"advgb-post-tax-term\">neurogenic<\/span>","<span class=\"advgb-post-tax-term\">neuropsychiatric<\/span>","<span class=\"advgb-post-tax-term\">Osteoarthritis<\/span>","<span class=\"advgb-post-tax-term\">PF-04457845<\/span>","<span class=\"advgb-post-tax-term\">pharmaceutical consulting<\/span>","<span class=\"advgb-post-tax-term\">Pharmaceutical Industry<\/span>","<span class=\"advgb-post-tax-term\">Sanofi<\/span>","<span class=\"advgb-post-tax-term\">Spring Works Therapeutics<\/span>","<span class=\"advgb-post-tax-term\">Tourette syndrome<\/span>","<span class=\"advgb-post-tax-term\">Vernalis<\/span>"]}},"comment_count":"0","relative_dates":{"created":"Posted 8 years ago","modified":"Updated 2 years ago"},"absolute_dates":{"created":"Posted on Jun 22, 2018","modified":"Updated on May 14, 2024"},"absolute_dates_time":{"created":"Posted on Jun 22, 2018 12:22 pm","modified":"Updated on May 14, 2024 2:27 pm"},"featured_img_caption":"","series_order":"","_links":{"self":[{"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/posts\/2675","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/comments?post=2675"}],"version-history":[{"count":1,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/posts\/2675\/revisions"}],"predecessor-version":[{"id":28016,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/posts\/2675\/revisions\/28016"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/media\/2705"}],"wp:attachment":[{"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/media?parent=2675"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/categories?post=2675"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/tags?post=2675"},{"taxonomy":"industry","embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/industry?post=2675"},{"taxonomy":"therapeutic_areas","embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/therapeutic_areas?post=2675"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}